Curis Appoints Dentzer as CFO

James E. Dentzer has been appointed chief financial and chief administrative officer, Curis, Inc. The company also promoted David Tuck, M.D. to the role of chief medical officer, and Mani Mohindru, Ph.D. to the role of chief strategy officer.
 
“I am excited with the expansion of our executive team,” said Ali Fattaey, Ph.D., Curis president and chief executive officer. “Jim brings to Curis a wealth of senior leadership and expertise through his experience at various companies. Jim, David and Mani are important additions to the company’s C-suite as we advance our drug candidates into later stages of development with the objective of bringing our drugs to cancer patients and creating long-term shareholder value.”
 
Mr. Dentzer joins the company from Dicerna Pharmaceuticals, where he served as chief financial officer. Previously, he helped finance and develop global biotechnology organizations as chief financial officer at Valeritas, Inc. and Amicus Therapeutics, Inc., and vice president and corporate controller of Biogen. He also held roles of increasing responsibility at DuPont, Kemper Financial Services, and Bank of America.
 
Dr. Tuck most recently served as the company’s senior vice president of Clinical and Translational Sciences. He joined the company from EMD Serono, where he served as senior medical director in the Oncology Translational Innovation program. Previously, Dr. Tuck was at Bristol-Myers Squibb Global Oncology Research in the role of Translational Physician for ipilimumab.
 
Dr. Mohindru most recently served as senior vice president of Corporate Strategy and Investor Relations. Previously, she spent several years as a Wall Street equity research analyst covering the biotechnology sector, including analyst roles at ThinkEquity LLC, Credit Suisse Securities and UBS Securities.